AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.3269
+0.0369 (12.72%)
Sep 11, 2026, 4:00 PM EDT - Market closed
AEON Biopharma Employees
AEON Biopharma had 8 employees as of December 31, 2025. The number of employees increased by 3 or 60.00% compared to the previous year.
Employees
8
Change (1Y)
3
Growth (1Y)
60.00%
Revenue / Employee
n/a
Profits / Employee
-$6,827,875
Market Cap
16.31M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | 3 | 60.00% |
| Dec 31, 2024 | 5 | -5 | -50.00% |
| Jun 30, 2024 | 5 | -4 | -44.44% |
| Dec 31, 2023 | 10 | 2 | 25.00% |
| Jun 30, 2023 | 9 | 0 | - |
| Dec 31, 2022 | 8 | - | - |
| Sep 30, 2022 | 9 | 3 | 50.00% |
| Jun 30, 2021 | 6 | - | - |
| Mar 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Enlivex | 34 |
| Cerenome | 28 |
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| BioCardia | 21 |
| PDS Biotechnology | 21 |
| Lisata Therapeutics | 21 |
| Dyadic International | 5 |
AEON News
- 4 days ago - Aeon Biopharma announces results from ABP-450 pilot forced degradation study - TheFly
- 4 days ago - AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX® - GlobeNewsWire
- 4 days ago - Aeon Biopharma initiated with a Buy at Laidlaw - TheFly
- 13 days ago - AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference - GlobeNewsWire
- 20 days ago - Aeon Biopharma designates Paul Lee as acting chief regulatory officer - TheFly
- 20 days ago - AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer - GlobeNewsWire
- 25 days ago - AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® - GlobeNewsWire
- 4 weeks ago - Aeon Biopharma price target lowered to $1.20 from $5 at H.C. Wainwright - TheFly